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High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients 
Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual 
Clinical Practice 
 
 
 
Madam d We would like to comment on the recent publication 
regarding the use of early docetaxel for hormone-sensitive prostate 
cancer from the STAMPEDE investigators in the Lancet [1] and also 
present our early experience of the risks of neutropenia and 
neutropenic sepsis of the first 39 patients treated at our centre with 
early docetaxel for hormone-sensitive prostate cancer since the trial 
results were first presented. 
 
The Velindre Cancer Centre was the largest recruiter 
internationally to the STAMPEDE trial; we have conse-quently been 
treating with early docetaxel for about 10 years within the trial and 
have a large body of experience in managing the relevant toxicity. 
 
Ninety-one per cent of patients were World Health Or-ganization 
performance status 0 and 1; 36% were aged 70e80 years and 64% 
were under 70 years; their median age was 66 years (compared with 
65 years in STAMPEDE); 59% were metastatic, 36% high risk 
locally advanced non-metastatic and 5% had relapsed after previous 
radical treatment. 
 
Our observed rates of grade 3 and 4 neutropenia were 14/ 39 
(36%) and rates of grade 3 and 4 neutropenic sepsis were 8/39 
(20%). Both of these are significantly higher than that observed in the 
STAMPEDE trial: 12% for both. 
 
It has previously been observed that clearance of doce-taxel 
increases by about 100% in castrate patients compared with those 
who are hormone naïve (with a two-fold reduction in the area under 
the curve) [2]. This may explain the higher toxicity observed in our 
cohort when compared with those receiving docetaxel in the castrate-
resistant setting, but not the difference when compared with those 
published in the STAMPEDE trial (the median time from initiation 
of hormones to starting docetaxel in 
 
 
 
 
 
our cohort was 9 weeks versus 8.6 weeks in the STAMPEDE trial). 
 
We draw a number of conclusions from these findings. First, early 
docetaxel is not a risk-free strategy, despite the impressive survival 
benefits observed in the published data. This is of particular 
relevance when discussing treatment options with the non-metastatic 
high risk locally advanced patient where there is no proven overall 
survival advantage. Second, consideration might be given to the role 
of growth factor prophylaxis during treatment, especially if the true 
rate of haematological toxicity is similar to that observed in our 
study. Third, clinical trial results do not always directly translate into 
real life clinical practice. We recommend that other centres 
prospectively audit their rates of neutropenia in the initial stages of 
implementation of the STAMPEDE results. 
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